Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Short-chain dehydrogenases/reductases (SDRs), such as DHRS3, catalyze the oxidation/reduction of a wide range of substrates, including retinoids and steroids (Haeseleer and Palczewski, 2000. Additionally we are shipping Dehydrogenase/reductase (SDR Family) Member 3 Proteins (4) and and many more products for this protein.
Showing 10 out of 60 products:
Human Polyclonal DHRS3 Primary Antibody for ICC, IF - ABIN4305162
Deisenroth, Itahana, Tollini, Jin, Zhang: p53-Inducible DHRS3 is an endoplasmic reticulum protein associated with lipid droplet accumulation. in The Journal of biological chemistry 2011
dhrs3 participates in atRA metabolism by reducing atRAL levels and is required for proper anteroposterior axis formation, neuroectoderm patterning, and somitogenesis.
Data show that dhrs3 was activated at the onset of gastrulation, and remained highly expressed at later stages of embryonic development.
Dhrs3a is thus an retinoic acid (RA)-induced feedback inhibitor of RA biosynthesis.
Yap (show YAP1 Antibodies) targets Dhrs3, to reduce retinoic acid synthesis and inhibit cardiac fibroblast differentiation during development.
Mouse Dhrs3 plays critical roles in the development of the heart by controlling the formation of retinoic acid.
The retinaldehyde reductase DHRS3 is essential for preventing the formation of excess retinoic acid during mouse embryonic development
we proposed that four newly identified peripheral blood mononuclear cells-derived genes( DHRS3, TTC38, SAP30BP (show SAP30BP Antibodies) and LPIN2 (show LPIN2 Antibodies) )could be integrated with previously reported rheumatoid arthritis (RA)-associated genes to monitor and/or diagnose RA.
the bifunctional nature of retinoid oxidoreductase (show TXNRD1 Antibodies) complex provides the RA-based signaling system with robustness by safeguarding appropriate RA concentration despite naturally occurring fluctuations in RDH10 (show RDH10 Antibodies) and DHRS3.
Data indicate that retinaldehyde reductase (DHRS3) requires retinol dehydrogenase 10 (RDH10 (show RDH10 Antibodies)) for full enzymatic activity and, in turn, activates RDH10 (show RDH10 Antibodies).
p53 (show TP53 Antibodies)-Inducible DHRS3 is an endoplasmic reticulum protein (show PDIA3 Antibodies) associated with lipid droplet accumulation.
The retSDR1 is identified as novel transcriptional target of the p53 (show TP53 Antibodies) family and not transactivated by EEC syndrome-specific mutations of TAp63gamma.
CST6 (show CST6 Antibodies), CXCL14 (show CXCL14 Antibodies), DHRS3, and SPP1 (show SPP1 Antibodies) are regulated by BRAF (show BRAF Antibodies) signaling and may play a role in papillary thyroid carcinoma pathogenesis
DHRS3 is important in limiting the formation of retinoic acid to ensure the proper development of the coronary vasculature.
Reduction of retinaldehyde by DHRS3 is critical for preventing formation of excess ATRA during embryonic development.
Short-chain dehydrogenases/reductases (SDRs), such as DHRS3, catalyze the oxidation/reduction of a wide range of substrates, including retinoids and steroids (Haeseleer and Palczewski, 2000
short-chain dehydrogenase/reductase 3
, dehydrogenase/reductase 3
, dehydrogenase/reductase (SDR family) member 3
, retinal short-chain dehydrogenase/reductase 1
, short chain dehydrogenase/reductase family 16C, member 1
, short-chain dehydrogenase/reductase 1
, retinal dehydrogenase/reductase family member 3